The company, a subsidiary of Biocon, is based in Boston and has access to the U.S. innovation ecosystem, which accelerates the development of cutting-edge cancer therapies. Bicara's bifunctional antibodies deliver an immunomodulatory payload directly to the tumor microenvironment, potentially offering long-lasting efficacy by ramping up immune cell activity. The company's biologics bring together the precision of targeted therapy and the power of tumor modulators, pioneering rapid and cost-effective breakthrough innovation.